VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR TQB2102 WITH CIPLA

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL TRIAL OF KYLO-11 “LPA SIRNA” PRESENTED AT ESC 2026 AND PUBLISHED IN THE LANCET

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON LM-364 “NECTIN-4TME ADC” APPROVED BY NMPA AND FDA

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQF6422 INJECTION "ACTRIIA/B MONOCLONAL ANTIBODY" APPROVED BY THE NMPA

INTERIM DIVIDEND FOR 2026

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

VOLUNTARY ANNOUNCEMENT - BENMELSTOBART IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY SEQUENTIAL COMBINATION WITH ANLOTINIB APPROVED AS FIRST-LINE TREATMENT FOR SQUAMOUS NON-SMALL CELL LUNG CANCER

VOLUNTARY ANNOUNCEMENT – SECOND-GENERATION FLURBIPROFEN PATCH APPROVED FOR MARKETING